Healthtech startup CURAPOD has raised Rs 20 crore in a pre-Series A round led by early-stage investor V3 Ventures, with participation from 3i Partners and Ideaspring Capital. The capital will fund product development, market expansion and operational scaling as the company pushes its non‑drug, technology-led pain management devices into broader domestic and international markets.
Technology-driven, non-invasive approach to common pain
Founded in 2022 by Sri Velliyur and Surya Maguluri and operating under Litemed India, CURAPOD develops wearable medical devices targeting everyday and chronic musculoskeletal pain. Its primary customers include people with back and knee pain, muscle stiffness, sports injuries and joint discomfort.
The company’s flagship product uses photobiomodulation therapy—red and near‑infrared light delivered via a wearable platform—to reduce inflammation, enhance microcirculation and support cellular repair. This evidence‑based, non-invasive modality offers an alternative to medication-centric treatments and is positioned for daily, at‑home use.
Use of funds: product, app and manufacturing
CURA POD plans to allocate the Rs 20 crore to accelerate research and development, enhance device features and improve its companion mobile application for more personalised, data‑driven pain management. The funding will also support scaling of manufacturing capacity, supply‑chain optimisation and expansion of direct‑to‑consumer distribution.
To broaden market reach, the startup will increase presence across online marketplaces and strengthen partnerships with physiotherapy centres, hospitals, fitness centres and sports rehabilitation facilities.
Domestic consolidation with an eye on regulated overseas markets
While continuing to deepen its footprint in India, CURAPOD intends to pursue regulated international markets—particularly in Europe—by exploring partnerships and compliance pathways. The company aims to transition from a wellness‑oriented brand to a recognised medical devices player through clinical validation and regulatory alignment.
Investor rationale and sector context
Investors backing the round highlighted the large, under‑served market for chronic pain solutions and expressed confidence in CURAPOD’s combination of clinical credibility, wearable design and consumer accessibility. Chronic pain management is emerging as a significant healthtech opportunity globally and in India, driven by rising awareness of preventive care and rehabilitation.
The successful pre‑Series A raise reflects growing investor interest in startups that integrate medical science with consumer technology to deliver practical, evidence‑based care solutions.
